NCT07173985 Strategies for Optimizing a Mailed FIT Program in Appalachia
| NCT ID | NCT07173985 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Colonic Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 550 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 550 participants in total. It began in 2026-01-20 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed study is examining strategies for optimizing mailed fecal immunochemical test (FIT) programs. In doing so, it will assess the efficacy of two promising strategies, FIT kit materials and patient navigation delivery mode. These strategies may help to improve colorectal cancer screening rates.
Eligibility Criteria
Inclusion Criteria: * Resident of an Appalachian county * Medical visit at a participating health system in the past two years * Average-risk for colorectal cancer * Not currently within colorectal cancer screening guidelines Exclusion Criteria: \-
Contact & Investigator
Paul Reiter, PhD
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07173985 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 74 Years, studying Colonic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07173985 currently recruiting?
Yes, NCT07173985 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ohio State University Comprehensive Cancer Center to inquire about joining.
Where is the NCT07173985 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT07173985 clinical trial?
NCT07173985 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Paul Reiter, PhD at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 550 participants.